Collegium Pharmaceutical, Inc.

Climate Impact & Sustainability Data (2022, 2023)

Investing in clean-in-place manufacturing systems, enabling wastewater to be recycled and thereby reducing freshwater consumption.
Packaging products in recyclable materials.
Repurposing unneeded information technology equipment through donations to STEM education non-profits, thereby reducing the impact of electronic waste.
Implementing two manufacturing process improvement initiatives that reduce processing time, resulting in decreased energy consumption.
Implementing in-office processes to minimize the use of consumables such as paper and plastic cups.
Operating under a hybrid model where employees are in the office part-time, thereby reducing car emissions associated with employee commuting.

Maintained excellent employee engagement (92% of employees completed the 2022 annual employee survey).
Initiated implementation of a multi-year Diversity, Equity, and Inclusion (DEI) strategic plan.
Donated over $350,000 in support of STEM charitable initiatives and charities providing clothing and food for community members in need.
Launched two programs to foster inclusivity and a sense of belonging among colleagues: Onboarding Ambassador Program and “Meet your new Collegium COLLeague” email introduction initiative.

Board of Directors provides guidance on strategic priorities and receives quarterly updates on ESG progress.
Executive Committee is responsible for strategic oversight and implementation of ESG and communicating ESG initiatives to the Board.
Employee-led Working Group convenes regularly to discuss ESG prioritization and implementation.

Evaluating the environmental impact of operations and exploring options to reduce the impact of the sales fleet and integrate hybrid and electric vehicles.
Implementing a multi-year DEI strategic plan with focus on attracting, developing, and retaining diverse talent; integrating DEI with business goals; and providing DEI education and resources.

Reviewing and updating vendor performance management policies to minimize resource use and waste generation, optimize raw materials, and improve environmental performance.

52% of company fleet transitioned to hybrid vehicles by December 2023, aiming for 75% by Q1 2024 and a fully hybrid fleet by 2025. This resulted in an 18-ton reduction in CO2 emissions and a 1.9 mpg improvement.
Implementation of clean-in-place manufacturing systems, enabling wastewater recycling and reducing freshwater consumption.
Two manufacturing process improvement initiatives reduced processing time, leading to decreased energy consumption.

Launched Collegium Pharmaceutical Scholarship Program with Scholarship America and Boston Red Sox/Science from Scientists STEM Booth.
Received Top Workplaces’ Culture Excellence Awards in Employee Well-Being, Employee Appreciation, and Professional Development categories.
89% employee engagement score (15% above Pharma Benchmark and 11% higher than previous year).
Launched a New Hire Ambassador Program for 13 new hires.
Hosted workshops on unconscious bias and inclusive leadership for 53 managers.
Annual Day of Service with approximately 180 hours of employee volunteer time.

Declassified the Board of Directors.
Introduced a new Environmental Management Policy and Lobbying and Political Expenses Statement.
Maintained a robust Compliance Program aligned with OIG-HHS guidance.

Short-term Goals:

Partnered with a third-party climate and sustainability expert for greenhouse gas emissions assessment.
Implemented various initiatives to improve employee experience, communication, and recognition.
FACT team reviews employee survey results and addresses areas for improvement.

Vendor Code of Conduct (includes environmental, human rights, health & safety, and business ethics considerations)